Who
Randy H. Thurman
Director
Company insider
Files Form 4 as: Director, Outlook Therapeutics; Director, TFF Pharmaceuticals; Director, Allscripts Healthcare Solutions; Executive Chairman, Presbia; Director, Arno Therapeutics; Director, Orthofix Medical; Chairman, President & CEO, CardioNet; Chairman, President & CEO, Viasys Healthcare.
In numbers
- Trades disclosed
- 901
- Buys
- 12
- Sells
- 39
- Bought
- $421K
- Sold
- $11.8M
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 3 Jan 2006
- Last trade
- 26 May 2026
- Last filed
- 27 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 May 2026filed 27 May 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,1455,000 at $0.429 | filing |
| 26 May 2026filed 27 May 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,1505,000 at $0.43 | filing |
| 1 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,734 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,636 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —89,549 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,441 at $0.00 | filing |
| 29 Mar 2023filed 31 Mar 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,065 at $0.00 | filing |
| 29 Sep 2022filed 30 Sep 2022 | TFF Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —40,255 at $0.00 | filing |
| 29 Sep 2022filed 30 Sep 2022 | TFF Pharmaceuticals | SEC FORM 4 Code M | $101K40,255 at $2.50 | filing |
| 29 Sep 2022filed 30 Sep 2022 | TFF Pharmaceuticals | SEC FORM 4 Sold | $173K40,255 at $4.29 | filing |
| 23 Mar 2022filed 24 Mar 2022 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,878 at $0.00 | filing |
| 18 May 2021filed 19 May 2021 | TFF Pharmaceuticals | SEC FORM 4 Bought | $9,8701,050 at $9.40 | filing |
| 24 Mar 2021filed 26 Mar 2021 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,873 at $0.00 | filing |
| 13 Nov 2020filed 13 Nov 2020 | TFF Pharmaceuticals | SEC FORM 4 Sold | $86K5,000 at $17.17 | filing |
| 11 Nov 2020filed 13 Nov 2020 | TFF Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —34,504 at $0.00 | filing |
| 11 Nov 2020filed 13 Nov 2020 | TFF Pharmaceuticals | SEC FORM 4 Code M | $86K34,504 at $2.50 | filing |
| 11 Nov 2020filed 13 Nov 2020 | TFF Pharmaceuticals | SEC FORM 4 Sold | $549K34,504 at $15.91 | filing |
| 5 Oct 2020filed 5 Oct 2020 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $202K396,809 at $0.51 | filing |
| 1 Oct 2020filed 5 Oct 2020 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —259,297 at $0.00 | filing |
| 14 Sep 2020filed 15 Sep 2020 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,20010,000 at $0.62 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Outlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerOTLK · manilatimes.net · 9 Oct 2026Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor DiscussionOTLK · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Randy H. Thurman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.